- Home
- CRVS vs WIA Comparison
CRVS vs WIA Comparison
Compare CRVS & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- WIA
- Stock Information
- Founded
- CRVS 2014
- WIA 2003
- Country
- CRVS United States
- WIA United States
- Employees
- CRVS N/A
- WIA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- WIA Trusts Except Educational Religious and Charitable
- Sector
- CRVS Health Care
- WIA Finance
- Exchange
- CRVS Nasdaq
- WIA Nasdaq
- Market Cap
- CRVS 206.5M
- WIA 188.0M
- IPO Year
- CRVS 2016
- WIA N/A
- Fundamental
- Price
- CRVS $3.63
- WIA $8.22
- Analyst Decision
- CRVS Strong Buy
- WIA
- Analyst Count
- CRVS 3
- WIA 0
- Target Price
- CRVS $15.67
- WIA N/A
- AVG Volume (30 Days)
- CRVS 906.6K
- WIA 39.2K
- Earning Date
- CRVS 05-05-2025
- WIA 01-01-0001
- Dividend Yield
- CRVS N/A
- WIA 12.29%
- EPS Growth
- CRVS N/A
- WIA N/A
- EPS
- CRVS N/A
- WIA N/A
- Revenue
- CRVS N/A
- WIA N/A
- Revenue This Year
- CRVS N/A
- WIA N/A
- Revenue Next Year
- CRVS N/A
- WIA N/A
- P/E Ratio
- CRVS N/A
- WIA N/A
- Revenue Growth
- CRVS N/A
- WIA N/A
- 52 Week Low
- CRVS $1.43
- WIA $7.56
- 52 Week High
- CRVS $10.00
- WIA $8.91
- Technical
- Relative Strength Index (RSI)
- CRVS 55.04
- WIA 53.72
- Support Level
- CRVS $3.15
- WIA $8.09
- Resistance Level
- CRVS $3.78
- WIA $8.26
- Average True Range (ATR)
- CRVS 0.25
- WIA 0.08
- MACD
- CRVS 0.12
- WIA 0.01
- Stochastic Oscillator
- CRVS 87.90
- WIA 80.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.